Your browser doesn't support javascript.
loading
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Podos, Steven D; Trachtman, Howard; Appel, Gerald B; Bomback, Andrew S; Dixon, Bradley P; Wetzels, Jack F M; Cook, H Terence; Parikh, Samir V; Pickering, Matthew C; Tumlin, James; Langman, Craig B; Lightstone, Liz; Sperati, C John; Daina, Erica; Bouman, Koenraad Peter; Rice, Kara; Thanassi, Jane A; Huang, Mingjun; Nester, Carla; Remuzzi, Giuseppe.
Affiliation
  • Podos SD; Discovery Research in Small Molecule Research, Alexion, AstraZeneca Rare Disease, New Haven, Connecticut, USA.
  • Trachtman H; Department of Pediatrics, NYU Grossman School of Medicine, New York, New York, USA.
  • Appel GB; Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Bomback AS; Division of Nephrology, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Dixon BP; Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Wetzels JFM; Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Cook HT; Department of Immunology and Inflammation, Centre for Inflammatory Disease, Faculty of Medicine, Imperial College London, London, UK.
  • Parikh SV; Division of Nephrology, The Ohio State University Medical Center, Columbus, Ohio, USA.
  • Pickering MC; Department of Immunology and Inflammation, Centre for Inflammatory Disease, Faculty of Medicine, Imperial College London, London, UK.
  • Tumlin J; Georgia Nephrology, Lawrenceville, Georgia, USA.
  • Langman CB; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Lightstone L; Department of Immunology and Inflammation, Centre for Inflammatory Disease, Faculty of Medicine, Imperial College London, London, UK.
  • Sperati CJ; Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Daina E; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
  • Bouman KP; ZNA Nierkliniek, Antwerp, Belgium.
  • Rice K; Department of Quantitative Sciences, Alexion, AstraZeneca Rare Disease, Boston, Massachusetts, USA.
  • Thanassi JA; Discovery Research in Small Molecule Research, Alexion, AstraZeneca Rare Disease, New Haven, Connecticut, USA.
  • Huang M; Discovery Research in Small Molecule Research, Alexion, AstraZeneca Rare Disease, New Haven, Connecticut, USA.
  • Nester C; Stead Family Children's Hospital - Divisions of Nephrology, University of Iowa, Iowa City, Iowa, USA.
  • Remuzzi G; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Am J Nephrol ; 53(10): 675-686, 2022.
Article in En | MEDLINE | ID: mdl-36404708
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glomerulonephritis, Membranoproliferative / Kidney Diseases Limits: Adult / Humans Language: En Journal: Am J Nephrol Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Glomerulonephritis, Membranoproliferative / Kidney Diseases Limits: Adult / Humans Language: En Journal: Am J Nephrol Year: 2022 Document type: Article Affiliation country: Country of publication: